Pathogenica Inc. Company Profile
Pathogenica, based in Cambridge, MA, was founded in 2009 to
pioneer commercial applications of pathogen sequencing.
Pathogenica applies next generation DNA sequencing
technology for rapid multiplex identification of pathogens,
drug resistance genes, and toxins in patient samples. The
founding scientific advisory board (SAB) is comprised of
distinguished scientists in the field, including George
Church, Harvard Medical School; Ron Davis, Stanford
University; W. Ian Lipkin, Columbia University; Andrew
Onderdonk, Harvard Medical School; and Kun Zhang, University
Pathogenica's high throughput pathogen detection system is
expected to enable rapid and highly sensitive detection of a
wide variety of pathogens from patient samples using just a
common assay protocol.
News from Pathogenica Inc.:
Pathogenica Achieves CE Marking for HAI BioDetection Kit
BOSTON, Aug. 14, 2013 /PRNewswire/ – Pathogenica, Inc. (www.pathogenica.com) announced today that the company has achieved the CE mark under the European Directive on In Vitro Diagnostic Medical Devices for its HAI BioDetection kit that runs on the Ion PGM™ benchtop sequencer. Thi…
Pathogenica Signs Agreement with Illumina
Companies to co-market Pathogenica HAI kit for MiSeq in Asia Pacific
BOSTON, July 17, 2013 /PRNewswire/ – Pathogenica Inc. announced today it had entered into an agreement with Illumina, whereby the parties will co-market in the Asia Pacific region a new version of Pathogenica’s HAI Bi…
Pathogenica CSO Speaks at IBC Life Sciences Drug Discovery & Diagnostic Development Week
CAMBRIDGE, Mass., Aug. 2, 2011 — Pathogenica, Inc. announced that the Company’s Chief Scientific Officer, Graeme Doran, Ph.D., is speaking today at the IBC Life Sciences Drug Discovery & Diagnostic Development Week, in San Francisco.
During the conference, the only event on the app…